CN Patent

CN115066254A — 用于吸入治疗炎症性肺病的人抗炎肽

Assigned to Adevita Life Sciences Co ltd · Expires 2022-09-16 · 4y expired

What this patent protects

本发明涉及人抗炎肽在炎症性肺病的吸入治疗中的用途。本发明特别涉及血管活性肠肽、C型利钠肽、B型利钠肽、垂体腺苷酸环化酶激活肽、肾上腺髓质素、α‑黑素细胞刺激激素、松弛素和干扰素γ的用于所述目的的用途。公开了含有此类人抗炎肽的气溶胶的有利特征和用于制备所述气溶胶的方法。本发明还涉及用于吸入治疗炎症性肺病的试剂盒。一个方面涉及CoViD‑19相关ARDS的治疗。

USPTO Abstract

本发明涉及人抗炎肽在炎症性肺病的吸入治疗中的用途。本发明特别涉及血管活性肠肽、C型利钠肽、B型利钠肽、垂体腺苷酸环化酶激活肽、肾上腺髓质素、α‑黑素细胞刺激激素、松弛素和干扰素γ的用于所述目的的用途。公开了含有此类人抗炎肽的气溶胶的有利特征和用于制备所述气溶胶的方法。本发明还涉及用于吸入治疗炎症性肺病的试剂盒。一个方面涉及CoViD‑19相关ARDS的治疗。

Drugs covered by this patent

Patent Metadata

Patent number
CN115066254A
Jurisdiction
CN
Classification
—
Expires
2022-09-16
Drug substance claim
No
Drug product claim
No
Assignee
Adevita Life Sciences Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.